Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences

被引:222
作者
Viles-Gonzalez, JF [1 ]
Fuster, V [1 ]
Badimon, JJ [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Cardiovasc Biol Res Lab, New York, NY 10029 USA
关键词
atherothrombosis; atherosclerosis; tissue factor; antithrombotic therapy; antiplatelet therapy; noninvasive imaging;
D O I
10.1016/j.ehj.2004.03.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherothrombosis, characterised by atherosclerotic lesion disruption with superimposed thrombus formation, is the major cause of acute coronary syndromes (ACS) and cardiovascular death. It is the leading cause of mortality in the industrialised world. Atherosclerosis is a diffuse process that starts early in childhood and progresses asymptomaticalty through adult life. Later in life, it is clinically manifested as coronary artery disease, stroke, transient ischaemic attack, and peripheral arterial disease. From the clinical point of view, we should envision this disease as a single pathologic entity that affects different vascular territories. Available antithrombotic therapy is very safe and efficient but the morbidity and mortality due to atherothrombosis is still unacceptably high. Recent evidence suggests that inhibition of tissue factor or elements in the tissue factor pathway (i.e., factors VIIa and Xa, or thrombin) has the potential to further improve outcomes in atherothrombosis. Here, we will review the most important concepts and advances in the pathogenesis, prevention, and antithrombotic treatment of this widespread disease. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1197 / 1207
页数:11
相关论文
共 110 条
[21]  
Cohen A, 1997, CIRCULATION, V96, P3838
[22]   Atherosclerosis of the thoracic aorta: From risk stratification to treatment [J].
Cohen, A ;
Amarenco, P .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (12) :1333-+
[23]   A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [J].
Cohen, M ;
Demers, C ;
Gurfinkel, EP ;
Turpie, AGG ;
Fromell, GJ ;
Goodman, S ;
Langer, A ;
Califf, RM ;
Fox, KAA ;
Premmereur, J ;
Bigonzi, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) :447-452
[24]  
Corti R, 2001, ANN NY ACAD SCI, V947, P181
[25]   Pathogenetic concepts of acute coronary syndromes [J].
Corti, R ;
Fuster, V ;
Badimon, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :7S-14S
[26]   Lipid lowering by simvastatin induces regression of human atherosclerotic lesions - Two years' follow-up by high-resolution noninvasive magnetic resonance imaging [J].
Corti, R ;
Fuster, V ;
Fayad, ZA ;
Worthley, SG ;
Helft, G ;
Smith, D ;
Weinberger, J ;
Wentzel, J ;
Mizsei, G ;
Mercuri, M ;
Badimon, JJ .
CIRCULATION, 2002, 106 (23) :2884-2887
[27]   A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction - The PENTALYSE study [J].
Coussement, PK ;
Bassand, JP ;
Convens, C ;
Vrolix, M ;
Boland, J ;
Grollier, G ;
Michels, R ;
Vahanian, A ;
Vanderheyden, M ;
Rupprecht, HJ ;
Van de Werf, F .
EUROPEAN HEART JOURNAL, 2001, 22 (18) :1716-1724
[28]   Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses [J].
Danesh, J ;
Whincup, P ;
Walker, M ;
Lennon, L ;
Thomson, A ;
Appleby, P ;
Gallimore, JR ;
Pepys, MB .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7255) :199-204
[29]   Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile [J].
Dangas, G ;
Badimon, JJ ;
Smith, DA ;
Unger, AH ;
Levine, D ;
Shao, JH ;
Meraj, P ;
Fier, C ;
Fallon, JT ;
Ambrose, JA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (05) :1294-1304
[30]  
DAVIES SW, 1993, BRIT HEART J, V69, P3